Primary and secondary endpoints achieved, including 86% abstinence over 6 months post treatment and no serious adverse events. TORONTO, CANADA, 11 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…

Groundbreaking Psychedelic study will investigate Binge Eating Disorder, Compulsive Sexual Behavior, and Internet Gaming Disorder TORONTO, CANADA, 05 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:954) (Awakn), a biotechnology company developing…

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding shares. TORONTO, CANADA, 04 January 2022 – Awakn Life Sciences Corp….

TORONTO, CANADA, 15 DECEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN)  (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat…

TORONTO, CANADA, December 14, 2021 – Awakn Life Sciences Corp. (NEO: AWKN)  (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the appointment…

Kate Butler To Be Appointed CFO, Jonathan Held, Current CFO, To Be Appointed Chief Business Officer. TORONTO, CANADA, 30 November 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’…

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III Toronto, Ontario (November 16, 2021) – Awakn Life Sciences Corp….

Worlds’s First Controlled Study To Investigate Ketamine-Assisted Psychotherapy TORONTO, CANADA, November 4, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines…

Toronto, Ontario–(Newsfile Corp. – November 2, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies)…

This Further Defines Development Pathways For Next Generation Of Psychedelic Medicines To Treat Addiction. TORONTO, CANADA, October 28, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology…

TORONTO, CANADA, 22 OCTOBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Chief…

The clinic will begin delivering ketamine-assisted psychotherapy treatments in October. TORONTO, CANADA, 20 October 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…